Aripiprazole Tablet
Product Images NDC 50090-4863

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-4863). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A line graph comparing the proportion of relapse over time between Aripiprazole and a placebo. The x-axis represents days from randomization with the number of subjects at risk below, and the y-axis indicates the proportion with relapse. Aripiprazole is shown with a solid blue line, exhibiting lower relapse proportions compared to the dashed red line representing placebo over a 182-day period.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A Kaplan-Meier survival curve comparing the proportion of subjects with relapse over 364 days from randomization between Aripiprazole and placebo groups. The graph includes a legend and a table showing the number of subjects at risk at various intervals for both groups, with Aripiprazole represented by a solid blue line and placebo by a dashed red line.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A horizontal bar graph titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the effects of various inhibitors and other drugs on pharmacokinetic parameters AUC and Cmax relative to reference without interacting drug. The graph includes data for CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducer (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam), each with error bars indicating the 90% confidence intervals.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A forest plot chart depicting fold changes with 90% confidence intervals for various drugs and enzymes relative to a reference without interacting drugs. The chart lists CYP2D6, dextromethorphan, CYP2C9, 2C19, warfarin (S- and R-forms), omeprazole, UGT1A4, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram, showing their pharmacokinetic parameters such as AUC and Cmax changes.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart showing aripiprazole fold change and 90% confidence intervals for variables including CYP2D6 metabolism status, gender, age, hepatic impairment, and severe renal impairment. The x-axis represents change relative to reference, charting parameters AUC and Cmax.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A pharmacokinetic chart showing fold change and 90% confidence intervals for Dehydro-Aripiprazole comparing several factors. The variables on the y-axis include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis displays the change relative to reference values for AUC and Cmax.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart titled "Aripiprazole Fold Change and 90% CI" showing changes in AUC and Cmax relative to a reference (without interacting drug) for various inhibitors and inducers. The x-axis represents fold change from 0.5 to 3.0. It includes CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs such as valproate, lithium, and lorazepam.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure of Aripiprazole, showing the molecular framework with chlorine-substituted phenyl ring, piperazine ring, and a quinolinone moiety linked by an ether chain.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier survival curve comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The X-axis shows days from randomization (0 to 182), while the Y-axis indicates the proportion with relapse (0 to 1.0). The chart includes a table below listing the number of subjects at risk at various time points for both treatment arms.*

FDA Label Image

Label Image (Lbl500904863)

Aripiprazole 20 mg oral tablets packaging label by A-S Medication Solutions. The label indicates a quantity of 30 tablets per package. It includes the product NDC 50090-4863 and storage instructions at 77 degrees Fahrenheit. The label also features a QR code and dosing information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.